Statistical analysis of antimicrobial percentage susceptibility (%S) in S. pneumoniae
| . | CLSI %S . | . | . | ||
|---|---|---|---|---|---|
| Antimicrobial . | 2002–03 . | 2004–05 . | 2007–09 . | P value . | Conclusion . |
| Penicillin (oral) | 74.7 | 67.8 | 47.2 | <0.0001 | significant decrease in susceptibility |
| Amoxicillin/clavulanic acid | 100.0 | 98.7 | 97.7 | 0.116 | non-significant change in susceptibility |
| Cefaclor | 85.3 | 78.7 | 53.5 | <0.0001 | significant decrease in susceptibility |
| Clarithromycina | 85.3 | 82.7 | 61.9 | <0.0001 | significant decrease in susceptibility |
| . | CLSI %S . | . | . | ||
|---|---|---|---|---|---|
| Antimicrobial . | 2002–03 . | 2004–05 . | 2007–09 . | P value . | Conclusion . |
| Penicillin (oral) | 74.7 | 67.8 | 47.2 | <0.0001 | significant decrease in susceptibility |
| Amoxicillin/clavulanic acid | 100.0 | 98.7 | 97.7 | 0.116 | non-significant change in susceptibility |
| Cefaclor | 85.3 | 78.7 | 53.5 | <0.0001 | significant decrease in susceptibility |
| Clarithromycina | 85.3 | 82.7 | 61.9 | <0.0001 | significant decrease in susceptibility |
aClarithromycin data in 2002–03 from Etests incubated in 5% CO2 and ambient atmosphere in 2004–05 and 2007–09, with differing associated breakpoints used as shown in Table 1.
Statistical analysis of antimicrobial percentage susceptibility (%S) in S. pneumoniae
| . | CLSI %S . | . | . | ||
|---|---|---|---|---|---|
| Antimicrobial . | 2002–03 . | 2004–05 . | 2007–09 . | P value . | Conclusion . |
| Penicillin (oral) | 74.7 | 67.8 | 47.2 | <0.0001 | significant decrease in susceptibility |
| Amoxicillin/clavulanic acid | 100.0 | 98.7 | 97.7 | 0.116 | non-significant change in susceptibility |
| Cefaclor | 85.3 | 78.7 | 53.5 | <0.0001 | significant decrease in susceptibility |
| Clarithromycina | 85.3 | 82.7 | 61.9 | <0.0001 | significant decrease in susceptibility |
| . | CLSI %S . | . | . | ||
|---|---|---|---|---|---|
| Antimicrobial . | 2002–03 . | 2004–05 . | 2007–09 . | P value . | Conclusion . |
| Penicillin (oral) | 74.7 | 67.8 | 47.2 | <0.0001 | significant decrease in susceptibility |
| Amoxicillin/clavulanic acid | 100.0 | 98.7 | 97.7 | 0.116 | non-significant change in susceptibility |
| Cefaclor | 85.3 | 78.7 | 53.5 | <0.0001 | significant decrease in susceptibility |
| Clarithromycina | 85.3 | 82.7 | 61.9 | <0.0001 | significant decrease in susceptibility |
aClarithromycin data in 2002–03 from Etests incubated in 5% CO2 and ambient atmosphere in 2004–05 and 2007–09, with differing associated breakpoints used as shown in Table 1.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
